Rosiglitazone Treatment of Type 2 Diabetic db/db Mice Attenuates Urinary Albumin and Angiotensin Converting Enzyme 2 Excretion
Figure 1
Chronic treatment with rosiglitazone (10–20 mg/kg/day) normalized hyperglycemia and improved glucose tolerance in db/db mice.
(A) Non fasted blood glucose levels in control, control+rosiglitazone, db/db and db/db+rosiglitazone mice. Repeated measures two-way ANOVA using a Bonferroni’s posthoc test showed that treatment with rosiglitazone caused a significant decrease in blood glucose levels of db/db mice [F (3, 54) = 176.04], p<0.0001. Similarly, duration of treatment showed a significant decrease in blood glucose levels of db/db mice [F (21, 54) = 16.34], p<0.0001. Data are represented as mean ± SEM of group size (n = 6–8). (B) Glucose tolerance test in rosiglitazone treated and untreated lean control and db/db mice. After eight weeks of treatment with rosiglitazone, mice were fasted for 16 hours and dosed with glucose (1.5 g/kg I.P). Blood glucose levels were measured by tail tip bleed at 0, 15, 30, 60, 90 and 120 minutes post administration. *p<0.001 Vs age-matched lean control and lean control+rosiglitazone mice. #p<0.001, $p<0.01 Vs untreated db/db mice. Data are represented as mean ± SEM of group size (n = 6–8). (C) One-way ANOVA of area under curve showed that rosiglitazone significantly improved the glucose tolerance in db/db+rosiglitazone mice compared to untreated db/db mice. *p<0.001 Vs age-matched lean control mice. #p<0.05 Vs untreated db/db mice. Each bar represents mean ± SEM of group size (n = 6–8).